Many of the more common assays employ a positive selection strategy, utilizing ferromagnetic particle bound anti-EpCAM antibodies to select epithelial CTCs, based on the assumption that carcinoma cells typically express epithelial markers while white blood cells (WBCs) in the blood do not [22]. The gene discussed is EPCAM; the disease is carcinoma.